GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.

doi:10.1186/s12967-016-0877-x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.

Journal of translational medicine - 6 May 2016

Pietrantonio Filippo, Berenato Rosa, Maggi Claudia, Caporale Marta, Milione Massimo, Perrone Federica, Tamborini Elena, Baratti Dario, Kusamura Shigeki, Mariani Luigi, Niger Monica, Mennitto Alessia, Gloghini Annunziata, Bossi Ilaria, Settanni Giulio, Busico Adele, Bagnoli Pietro Francesco, Di Bartolomeo Maria, Deraco Marcello, de Braud Filippo

Abstract excerpt

BACKGROUND: There is lack of evidence about systemic treatment of pseudomyxoma peritonei (PMP) relapsing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. There is also lack of biomarkers able to predict outcomes beyond known clinical and pathological prognostic features. METHODS: Fifteen patients with relapsed PMP and progressive disease within the last 6 months were included and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bevacizumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Capecitabine

Share to Chromogranins

Share to Disease-Free Survival

Share to GTP-Binding Protein alpha Subunits, Gs

Share to Neoplasm Recurrence, Local

Share to Peritoneal Neoplasms

Share to Translational Research, Biomedical

Source

Open in PubMed Open full text

Identifiers

PMID: 27154293
DOI: 10.1186/s12967-016-0877-x
PMCID: PMC4859944

Genes

GNAS
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.PMID 27154293Read ↗

Toward the molecular dissection of peritoneal pseudomyxoma.Semantic proximity Read ↗

Targeted Genetic Sequencing Analysis of 223 Cases of Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Shows Survival Related to GNAS and KRAS Status.Semantic proximity Read ↗

Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy.Semantic proximity Read ↗

Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei.Semantic proximity Read ↗

Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry.Semantic proximity Read ↗

Progress on immuno-microenvironment and immune-related therapies in patients with pseudomyxoma peritonei.Semantic proximity Read ↗

Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei.Semantic proximity Read ↗

Analysis of Mutation and Loss of Heterozygosity by Whole-Exome Sequencing Yields Insights into Pseudomyxoma Peritonei.Semantic proximity Read ↗

Molecular profiles of high-grade and low-grade pseudomyxoma peritonei.Semantic proximity Read ↗

Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritoneiSemantic proximity Read ↗

Undetectable circulating tumor DNA confirms the inability of pseudomyxoma peritonei to systemic dissemination.Semantic proximity Read ↗

The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.